title: [A clinical experience of rokitamycin on Campylobacter enteritis. Research Group of Rokitamycin on Infectious Enteritis].
abstract: Rokitamycin, a newly developed macrolide, was administered to a total of 107 cases, 16 years old or more, in order to evaluate its clinical efficacy, safety and usefulness on Campylobacter enteritis. Daily dosage of 600 mg of rokitamycin was administered orally in three divided doses for 5 days. Bacteriological and clinical efficacies were judged by the attending doctors from the evaluation criteria made by the committee and from the days required for improvement of diarrhea, defervescence and so on, respectively. Antibacterial activities against the isolates were tested of rokitamycin (RKM), erythromycin (EM), josamycin (JM) and ofloxacin (OFLX). The results were as follows; 41 symptomatic patients and 5 carriers were evaluated. Clinical efficacy (n = 41) was 100% (excellent; 34.1%, good; 65.9%). Bacteriological efficacy (n = 41) was 97.6%. Eight of the 9 cases with consecutive stool cultures were free of the bacteria on and after one day of the drug administration. Clinical usefulness (n = 46) was 97.8%. Slight epigastric pain was seen in only one as a side effect. The items of abnormal laboratory findings were 4 elevated GPT and/or GOT and one increased number of WBC in 4 cases. MIC90 of RKM, EM, JM and OFLX against 41 clinical isolates of C. jejuni were 1.56, 3.13, 3.13 and 0.78 micrograms/ml, respectively. Rokitamycin was considered clinically useful to treat Campylobacter enteritis.
authors.affiliation: Department of Infectious Diseases, Tokyo Metropolitan Toshima General Hospital.
authors.forename: S
authors.initials: S
authors.lastname: Irimajiri
authors.forename: H
authors.initials: H
authors.lastname: Sagara
authors.forename: I
authors.initials: I
authors.lastname: Tomizawa
authors.forename: Y
authors.initials: Y
authors.lastname: Takizawa
authors.forename: Y
authors.initials: Y
authors.lastname: Nitta
authors.forename: T
authors.initials: T
authors.lastname: Seo
authors.forename: J
authors.initials: J
authors.lastname: Sato
authors.forename: T
authors.initials: T
authors.lastname: Tsunoda
authors.forename: S
authors.initials: S
authors.lastname: Ota
authors.forename: Y
authors.initials: Y
authors.lastname: Nakamura
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002169:Campylobacter Infections / Q000188:drug therapy*; D017000:Campylobacter coli; D016123:Campylobacter jejuni; D004341:Drug Evaluation; D004751:Enteritis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015644:Miocamycin / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D015644:Miocamycin; C033383:rokitamycin